code and readme file Search Results


95
Chem Impex International sodium chloride
Sodium Chloride, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/10__3390_slash_molecules30112371-160-26-29?v=Chem+Impex+International
Average 95 stars, based on 1 article reviews
sodium chloride - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

99
Akoya Biosciences secomam anthelie advanced 5 spectrophotometer
Secomam Anthelie Advanced 5 Spectrophotometer, supplied by Akoya Biosciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/10__1080_slash_10942910902741834-70-11-20?v=Akoya+Biosciences
Average 99 stars, based on 1 article reviews
secomam anthelie advanced 5 spectrophotometer - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

90
SAS institute cp2004.sas
Cp2004.Sas, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/pm15641426-311-58-61?v=SAS+institute
Average 90 stars, based on 1 article reviews
cp2004.sas - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
FUJIFILM imaging-plate reader bas-2500
Imaging Plate Reader Bas 2500, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/10__1107_slash_s0909049511009836-52-16-19?v=FUJIFILM
Average 90 stars, based on 1 article reviews
imaging-plate reader bas-2500 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare assembled transcripts files (gtf format)
Assembled Transcripts Files (Gtf Format), supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/pmc08145500-71-7-25?v=Johns+Hopkins+HealthCare
Average 90 stars, based on 1 article reviews
assembled transcripts files (gtf format) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

86
BioNimbus Inc neoantigen predictions pcawg tcga wgs vcf files
a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and <t>WGS</t> (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential <t>neoantigen</t> peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.
Neoantigen Predictions Pcawg Tcga Wgs Vcf Files, supplied by BioNimbus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/pmc10198624-489-5-20?v=BioNimbus+Inc
Average 86 stars, based on 1 article reviews
neoantigen predictions pcawg tcga wgs vcf files - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

90
qsr international nvivo qualitative analysis software
a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and <t>WGS</t> (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential <t>neoantigen</t> peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.
Nvivo Qualitative Analysis Software, supplied by qsr international, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/pmc01550694-60-10-16?v=qsr+international
Average 90 stars, based on 1 article reviews
nvivo qualitative analysis software - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

99
STATA Corporation stata 11
a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and <t>WGS</t> (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential <t>neoantigen</t> peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.
Stata 11, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/pmc03141069-100-11-13?v=STATA+Corporation
Average 99 stars, based on 1 article reviews
stata 11 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

90
Velotron Inc cs 2008 software
a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and <t>WGS</t> (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential <t>neoantigen</t> peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.
Cs 2008 Software, supplied by Velotron Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/jonathan_perry__2018__voluntary_performance_and_the_hemodynamic_response_in_the_prefrontal_cortex_during_exhaustive_exercise-470-26-26?v=Velotron+Inc
Average 90 stars, based on 1 article reviews
cs 2008 software - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

86
Gene Codes Inc sequencher
a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and <t>WGS</t> (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential <t>neoantigen</t> peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.
Sequencher, supplied by Gene Codes Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/collin_matthew_aric__2010__characterization_and_evolutionary_analyses_of_silk_fibroins_from_two_insect_orders_embioptera_and-903-20-21?v=Gene+Codes+Inc
Average 86 stars, based on 1 article reviews
sequencher - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

90
Endress+Hauser inc jena 384g qtower qpcr
a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and <t>WGS</t> (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential <t>neoantigen</t> peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.
Jena 384g Qtower Qpcr, supplied by Endress+Hauser inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/pmc11259706-250-16-14?v=Endress%2BHauser+inc
Average 90 stars, based on 1 article reviews
jena 384g qtower qpcr - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
CodonCode corporation codoncode aligner 3.5.6
a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and <t>WGS</t> (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential <t>neoantigen</t> peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.
Codoncode Aligner 3.5.6, supplied by CodonCode corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/code+and+readme+file/10__1111_slash_jbi__13578-66-9-8?v=CodonCode+corporation
Average 90 stars, based on 1 article reviews
codoncode aligner 3.5.6 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and WGS (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential neoantigen peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.

Journal: Nature biotechnology

Article Title: Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer

doi: 10.1038/s41587-021-01021-3

Figure Lengend Snippet: a. Approaches to identify potential nuORF-derived neoantigens. b-f. Potential neoantigens from nuORFs with somatic mutations. b. Percent of ORFs with median ≥30x read coverage y-axis) by WES (n = 18 samples: primary melanoma and GBM and matched normal) and WGS (n = 2 samples: MEL11 and matched normal, hashed) for different types of ORFs (x-axis) (*p < 0.01, t-test). Error bars: 95% CI. c. Number of Ribo-seq supported, non-synonymous SNVs (y-axis) in MEL11 in annotated ORFs, nuORFs, or in both ORF types when they overlap. d. Number of high affinity (<500 nM, netMHCpan v4.0) potential neoantigens (y-axis) from annotated ORFs (grey) and nuORFs (pink) in MEL11. e. The rate of SNV-derived potential neoantigen peptides with high binding affinity (<500 nM, netMHCpan v4.0) (y-axis) from annotated ORFs (grey) and nuORFs (pink) across 1,170 netMHCpan v4.0 trained HLA alleles (means: 1.4% annotated, 1.6% nuORFs (0.1–0.3% higher, CI 95%)). f. PCAWG-TCGA analysis of somatic SNVs in nuORFs. Percent of SNVs (y-axis) overall (light pink), supported by RNA-seq (pink), and nonsynonymous, supported by RNA-seq (dark pink) in three cancer types (x-axis). Bottom: number of samples analyzed. For all boxplots (E,F): median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown.

Article Snippet: Variant analysis, read coverage, and neoantigen predictions PCAWG-TCGA WGS VCF files for CLL, GBM and SKCM were accessed via ICGC Bionimbus ( https://icgc.bionimbus.org/ ) using the Gen3-client ( https://gen3.org/resources/user/gen3-client/ ).

Techniques: Derivative Assay, Immunopeptidomics, Binding Assay, RNA Sequencing

a. Approaches to identify potential nuORF-derived neoantigens. b. nuORFs have low sequence coverage by WES compared to WGS. Distribution of WES read coverage (x axis) across different ORF types (y axis). Bottom: WGS read coverage across all ORFs of all types. Vertical red line marks 30x coverage. n = 86421 (annotated), 61398 (lncRNA), 61248 (Out-of-frame), 33823 (5’ uORF), 31453 (3’ dORF), 20337 (5’ overlap uORF), 18316 (3’ overlap dORF), 7941 (Pseudogene), 2371 (Other), 323846 (WGS). Median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown. c. Somatic variants in the melanoma patient-derived cell line reflect the variants detected in the original tumor. Cancer-specific SNVs and InDels identified by WES from the primary tumor and by WGS from the tumor-derived cell line. d. Ribo-seq can be used to identify translated variants. Example of a translated SLC7A1 5’ uORF with a cancer-specific SNV. Top: histogram of Ribo-seq reads supporting the translation of the 5’ uORF. Middle: Ribo-seq reads supporting translation of the mutant (green) and wild-type alleles. Predicted neoantigen outlined in red.

Journal: Nature biotechnology

Article Title: Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer

doi: 10.1038/s41587-021-01021-3

Figure Lengend Snippet: a. Approaches to identify potential nuORF-derived neoantigens. b. nuORFs have low sequence coverage by WES compared to WGS. Distribution of WES read coverage (x axis) across different ORF types (y axis). Bottom: WGS read coverage across all ORFs of all types. Vertical red line marks 30x coverage. n = 86421 (annotated), 61398 (lncRNA), 61248 (Out-of-frame), 33823 (5’ uORF), 31453 (3’ dORF), 20337 (5’ overlap uORF), 18316 (3’ overlap dORF), 7941 (Pseudogene), 2371 (Other), 323846 (WGS). Median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown. c. Somatic variants in the melanoma patient-derived cell line reflect the variants detected in the original tumor. Cancer-specific SNVs and InDels identified by WES from the primary tumor and by WGS from the tumor-derived cell line. d. Ribo-seq can be used to identify translated variants. Example of a translated SLC7A1 5’ uORF with a cancer-specific SNV. Top: histogram of Ribo-seq reads supporting the translation of the 5’ uORF. Middle: Ribo-seq reads supporting translation of the mutant (green) and wild-type alleles. Predicted neoantigen outlined in red.

Article Snippet: Variant analysis, read coverage, and neoantigen predictions PCAWG-TCGA WGS VCF files for CLL, GBM and SKCM were accessed via ICGC Bionimbus ( https://icgc.bionimbus.org/ ) using the Gen3-client ( https://gen3.org/resources/user/gen3-client/ ).

Techniques: Immunopeptidomics, Derivative Assay, Sequencing, Mutagenesis

a. PCAWG-TCGA analysis of SNVs in annotated ORFs and nuORFs. Number of all, transcribed (RNA-seq support), and transcribed nonsynonymous SNVs (y axis) in annotated ORFs and nuORFs (x axis) in CLL, GBM, and SKCM. In CLL, 2/73 samples had no transcribed SNVs, and 3/73 patients had no transcribed nonsynonymous SNVs. n = 73 (CLL,All), 71 (CLL, Expressed), 70 (CLL, Expressed nonsynonymous), 33 (GBM), 36 (SKCM) independent samples. Median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown. b. nuORFs with SNVs are translated in unrelated CLL samples. Number (left) and fraction (right) of transcribed nonsynonymous nuORF SNVs detected across 70 CLL samples (y axis) with Ribo-seq TPM > 0 in 0 or more unrelated CLL samples profiled by Ribo-seq (x axis). c. Transcription frequently indicates translation for annotated ORFs and nuORFs. Percent of annotated (grey) and nuORFs (pink) with RNA-seq and Ribo-seq support (y axis) in two CLL samples (x axis).

Journal: Nature biotechnology

Article Title: Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer

doi: 10.1038/s41587-021-01021-3

Figure Lengend Snippet: a. PCAWG-TCGA analysis of SNVs in annotated ORFs and nuORFs. Number of all, transcribed (RNA-seq support), and transcribed nonsynonymous SNVs (y axis) in annotated ORFs and nuORFs (x axis) in CLL, GBM, and SKCM. In CLL, 2/73 samples had no transcribed SNVs, and 3/73 patients had no transcribed nonsynonymous SNVs. n = 73 (CLL,All), 71 (CLL, Expressed), 70 (CLL, Expressed nonsynonymous), 33 (GBM), 36 (SKCM) independent samples. Median, with 25% and 75% (box range), and 1.5 IQR (whiskers) are shown. b. nuORFs with SNVs are translated in unrelated CLL samples. Number (left) and fraction (right) of transcribed nonsynonymous nuORF SNVs detected across 70 CLL samples (y axis) with Ribo-seq TPM > 0 in 0 or more unrelated CLL samples profiled by Ribo-seq (x axis). c. Transcription frequently indicates translation for annotated ORFs and nuORFs. Percent of annotated (grey) and nuORFs (pink) with RNA-seq and Ribo-seq support (y axis) in two CLL samples (x axis).

Article Snippet: Variant analysis, read coverage, and neoantigen predictions PCAWG-TCGA WGS VCF files for CLL, GBM and SKCM were accessed via ICGC Bionimbus ( https://icgc.bionimbus.org/ ) using the Gen3-client ( https://gen3.org/resources/user/gen3-client/ ).

Techniques: RNA Sequencing